HOMEVULNERABILITIESCVE-2026-35617
MEDIUMPOC

CVE-2026-35617

CWE-807Published: April 9, 2026· Updated: Apr 16, 2026

5.4
CVSS v3.1
EPSS:0.05%probability of exploitation in 30 daysPercentile:14.8th

Official Description

OpenClaw before 2026.3.25 contains an authorization bypass vulnerability in Google Chat group policy enforcement that relies on mutable space display names. Attackers can rebind group policies by changing or colliding space display names to gain unauthorized access to protected resources.

NVD Source

Technical Analysis

CVE-2026-35617 can be exploited remotely over the network without requiring physical or adjacent access, significantly expanding the attack surface for threat actors.

Exploitation requires low privileges, which limits the exposure to scenarios where an attacker has already gained initial access.

A proof-of-concept (PoC) exploit exists for CVE-2026-35617. While not yet confirmed in active campaigns, the availability of PoC code increases exploitation risk substantially.

CVSS v3.1 Vector Breakdown

Exploitability
Attack VectorNetwork
Attack ComplexityLow
Privileges Req.Low
User InteractionNone
ScopeUnchanged
Impact
ConfidentialityLow
IntegrityLow
AvailabilityNone
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:N

Affected Vendors & Products

openclaw1 product
openclaw
Source: NVD CPE · 1 total CPE entries

Exploit & PoC Resources

POC AVAILABLEProof-of-concept code exists
External links open in a new tab. Always verify in a controlled environment before use.

Official Patches & Advisories

All References (3)

Quick Facts

CVE IDCVE-2026-35617
CVSS Score5.4 / 10
SeverityMEDIUM
WeaknessCWE-807
CISA KEVNo
ExploitPOC
EPSS (30d)0.05%
Affected1 vendor
PublishedApr 9, 2026

Related CVEs (CWE-807)

Recommended Actions

  • Apply vendor patches immediately
  • Monitor CVE-2026-35617 in threat intel feeds
  • Review IDS/IPS signatures for exploitation attempts
Data sourced from NVD (NIST), CISA KEV, and EPSS (FIRST). Analysis generated by CTIWATCH.COM. CVE data is provided under the NVD usage policy.